In this context, the clinical introduction of proteotoxic stress-targeting agents such as the proteasome inhibitors bortezomib [5], ixazomib [6], or carfilzomib [7] and the histone deacetylase inhibitor (HDAC) panobinostat [8] marked a new era of MM therapy. The gene discussed is HDAC9; the disease is Miyoshi myopathy.